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Abstract 
Background: Governments including the United Kingdom and Canada endeavour to optimise health 
care systems through investment in primary care reform. Community pharmacists are moving, 
encouraged by policy, to deliver self-care support in pharmacy. International studies indicate the role 
and scope of pharmacists in primary care could be expanded with clinical and economic savings. 
Methods: Chapter 1 presents a systematic review of randomized controlled trials evaluating self-
management support interventions following the Cochrane handbook and PRISMA guidelines. Chapter 
4 describes the qualitative research (a focus group with stakeholders, working meetings with general 
practitioners (GPs) to develop treatment pathways, and semi-structured interviews with community 
pharmacists) to co-design an Australian model minor ailment service (MAS) applicable to the Australian 
setting. Chapter 5 presents a protocol for a cluster-randomized controlled trial (cRCT) quantitatively 
evaluating the clinical, humanistic and economic effectiveness of MAS. MAS pharmacists were trained 
in treatment pathways pre-agreed with GPs and communication systems with GPs, and received 
monthly practice facilitator support. Control patients received usual pharmacist care (UC). Chapter 6 
details the statistical analysis undertaken using modified Poisson regression. Chapter 7 details the cost 
utility analysis (CUA) conducted alongside the cRCT. Deterministic and probabilistic sensitivity analysis 
were performed.  
Results: A theoretical model was developed providing structure to self-management in practice 
(Chapter 1). Chapter 4 presents the community pharmacy MAS model with the following elements: (1) 
In-pharmacy consultation, (2) treatment protocols on a technology platform (HealthPathways), (3) 
communication channels between pharmacy and GPs (HealthLink), (4) educational training, and (5) 
practice change support. Chapter 6 highlights findings from the cRCT. Patients (n=894) were recruited 
from 30 pharmacies and 82% (n=732) responded to follow up. Patients receiving MAS were 1.5 times 
more likely to receive an appropriate referral (relative rate (RR)=1.51; 95% confidence interval 
(CI)=1.07-2.11; p=0.018), and were 5 times more likely to adhere to referral, compared with UC patients 
(RR=5.08; 95%CI=2.02-12.79; p=0.001). MAS pharmacists were 2.6 times more likely to perform a 
clinical intervention (RR=2.62, 95%CI=1.28-5.38; p=0.009), compared with UC. MAS patients (94%) 
achieved symptom resolution or relief at follow up, while this was 88% with UC (RR=1.06; 95%CI=1-
1.13; p=0.035). MAS patients had a greater mean difference in EQ-VAS at follow up (4.08; 95%CI=1.23-
6.87; p=0.004). No difference in reconsultation was observed (RR=0.98; 95%CI=0.75-1.28; p=0.89). 
The CUA revealed MAS as cost-effective. MAS patients gained an additional 0.003 QALYs at an 
incremental cost of AUD $7.14, compared to UC. The resulting ICER was AUD $2,277/ QALY. The 
probabilistic SA revealed ICERs between AUD -$1,150 and $5,780/ QALY. 
Conclusion: Findings suggest MAS should be implemented within the Australian context. A series of 
recommendations are made including the development of self-care policy in Australia to provide a policy 
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Chapter 1 describes a systematic review of published literature (1). The review was undertaken as part 
of the early exploratory work to capture the breadth of literature around self-management support 
interventions to identify and describe the main components of self-management support from a large 
body of published literature. Early insights from the review suggested a dearth of published evidence 
relating to self-management in community pharmacy. It was then decided to expand the review to 
include published literature from other primary care disciplines. The findings captured and synthesized 
the overarching components of self-management into a theoretical model. The model consists of a one-
on-one consultation with a health care professional, such as a community pharmacist. The preliminary 
work contributed to understanding and investigating how self-management services could be practised 
in community pharmacy. 
Chapter 2 presents the contextual background information of this research by examining self-care and 
self-care models in community pharmacy. The role of the community pharmacist in relation to self-care 
and minor ailment services is described. The chapter concludes by highlighting the gaps and 
opportunities in practice and international literature detailing the premise for undertaking the research. 
Chapter 3 provides the aim and objectives of individual studies within the thesis and provides a 
description of the methodological approach to meet objectives. A detailed description of methods is 
presented under the relevant chapters of this thesis. 
Chapters 4-7 discusses the empirical studies undertaken, each addressing specific objectives. Chapter 
4 details a qualitative study undertaken with the aim of co-designing a MAS relevant to Australian 
community pharmacy (2). The co-design process involved an initial focus group with stakeholders to 
agree on service model elements and semi-structured interviews with community pharmacists during 
feasibility testing of the service. Chapter 5 details the protocol for a cRCT to evaluate the clinical, 
humanistic and economic impact of the community pharmacist delivered MAS (developed in chapter 4) 
compared to UC, in the Australian setting (3). Chapter 6 describes the clinical and humanistic evaluation 
results obtained from the cRCT (4). Chapter 7 details the results of the economic evaluation undertaken 
alongside the cRCT (5). 
 xii 
Chapter 8 discusses the overall research. The chapter focuses on describing how the research methods 
addressed the overall objectives and discusses contributions to existing knowledge in community 
pharmacy and the wider literature. The chapter reflects on the overall strengths and limitations of the 
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